RxDoctor Payments Data

Estelamari Rodriguez, MD

Hematology & Oncology · Miami, FLNPI 1194887034

Payments from drug & device makers

$1,152,600in general payments, 2019–2025

Across 731 payments — averaging $1576.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$320K
  • Merck$207K
  • Genentech, Inc.$114K
  • Pfizer$109K
  • Seagen Inc.$85K
  • Daiichi Sankyo Inc.$52K
  • plus $266K from 54 others
$3,200in research payments, 2019–2025

Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$3K

What the payments were for

  • Consulting fees$108,16462%
  • Speaking & faculty fees$39,72223%
  • Travel & lodging$11,1686%
  • Food & beverage$14,6658%
  • Education$2690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.20$320,393
Merck54$206,787
Genentech, Inc.10$113,867
Pfizer52$109,044
Seagen Inc.2$85,197
Daiichi Sankyo Inc.56$51,567
AstraZeneca(2 entities)83$45,568
Johnson & Johnson(2 entities)64$41,204
E.r. Squibb & Sons, L.L.C.46$34,019
Genentech USA, Inc.61$32,116
Janssen Research & Development, LLC1$22,070
F. Hoffmann-la Roche AG3$19,404
Astrazeneca UK Limited11$14,763
AbbVie5$10,683
Boehringer Ingelheim11$10,315
Lilly USA, LLC24$7,464
Amgen9$6,188
Regeneron9$5,743
Regeneron Healthcare Solutions, Inc.21$4,769
Novartis31$2,457
Eisai Inc.8$2,422
G1 Therapeutics, Inc.2$1,604
Janssen Scientific Affairs, LLC3$1,177
Novocure Inc.8$1,028
Gilead7$384
EMD Serono, Inc.30$280
Array Biopharma Inc16$277
Caris MPI, Inc.6$254
Bristol Myers Squibb10$150
Incyte Corporation10$148
Janssen Global Services, LLC1$145
Tesaro, Inc.7$112
Immunocore Limited4$101
Astellas Pharma US Inc6$99
Coherus Oncology, Inc.1$85
Bayer3$64
Rigel Pharmaceuticals, Inc.3$49
Jazz Pharmaceuticals Inc.2$44
Stemline Therapeutics Inc.2$44
Dova Pharmaceuticals3$43
GSK2$42
Exelixis Inc.3$41
Sanofi2$34
Helsinn Therapeutics (U.S.), Inc.2$31
Tersera Therapeutics LLC1$31
Foundation Medicine, Inc.1$29
Mylan Institutional Inc.1$24
Myriad Genetic Laboratories, Inc.1$22
Tempus AI, Inc1$20
Catalyst Pharmaceuticals, Inc.1$20
Mirati Therapeutics, Inc.1$19
Clovis Oncology, Inc.1$19
Pharmacyclics LLC, An Abbvie Company1$19
Genmab U.S., Inc.1$18
Pharmacosmos Therapeutics Inc.1$18
Kyowa Kirin, Inc.1$18
Verastem, Inc.1$18
EUSA Pharma (US) LLC1$15
Ipsen Biopharmaceuticals, Inc1$13
Agios Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,152,600 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$114,501
Medicare patients
259
Services billed
1,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate120$2,007,132
IbrancePalbociclib29$439,060
TabrectaCapmatinib Hydrochloride15$322,801
RetevmoSelpercatinib13$276,590
LorbrenaLorlatinib13$261,865
ErivedgeVismodegib12$160,351
Everolimus11$11,013
EliquisApixaban11$6,465
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$548
Anastrozole24$535
Gabapentin30$424
Dexamethasone28$409
Prochlorperazine Maleate32$339
Ondansetron Hcl53$305
Oxycodone Hcl13$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$45,568$2,007,132120 claims
PfizerIbrance, Lorbrena, Eliquis$109,044$707,39053 claims
NovartisTabrecta$2,457$322,80115 claims
Lilly USA, LLCRetevmo$7,464$276,59013 claims
Genentech USA, Inc.Erivedge$32,116$160,35112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →